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Abstract
To better understand envenoming and to facilitate the development of new therapies for snakebite victims, rapid, sensitive, and
robust methods for assessing the toxicity of individual venom proteins are required. Metalloproteinases comprise a major protein
family responsible for many aspects of venom-induced haemotoxicity including coagulopathy, one of the most devastating
effects of snake envenomation, and is characterized by fibrinogen depletion. Snake venoms are also known to contain anti-
fibrinolytic agents with therapeutic potential, which makes them a good source of new plasmin inhibitors. The protease plasmin
degrades fibrin clots, and changes in its activity can lead to life-threatening levels of fibrinolysis. Here, we present a methodology
for the screening of plasmin inhibitors in snake venoms and the simultaneous assessment of general venom protease activity.
Venom is first chromatographically separated followed by column effluent collection onto a 384-well plate using
nanofractionation. Via a post-column split, mass spectrometry (MS) analysis of the effluent is performed in parallel. The
nanofractionated venoms are exposed to a plasmin bioassay, and the resulting bioassay activity chromatograms are correlated
to the MS data. To study observed proteolytic activity of venoms in more detail, venom fractions were exposed to variants of the
plasmin bioassay in which the assay mixture was enriched with zinc or calcium ions, or the chelating agents EDTA or 1,10-
phenanthroline were added. The plasmin activity screening system was applied to snake venoms and successfully detected
compounds exhibiting antiplasmin (anti-fibrinolytic) activities in the venom of Daboia russelii, and metal-dependent proteases
in the venom of Crotalus basiliscus.
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Introduction
Plasmin is a trypsin-like enzyme, which plays a crucial role in
the fibrinolytic pathway where it hydrolyses blood clots and
maintains normal hemostasis. Plasmin originates from plas-
minogen, and is activated by tissue plasminogen activator
(tPA) or urokinase plasminogen activator (uPA) [1].
Although the fibrinolytic activity of plasmin is regulated by
the physiological inhibitors α2-antiplasmin and α2-macro-
globulin, in many cases (e.g., major surgeries, hemophilia,
vonWillebrand syndrome, heavy menstrual bleeding), medic-
inal exogenous inhibitors are required to properly control its
activity [1, 2]. Examples of plasmin inhibitors currently used
successfully in the clinic are ε-aminocaproic acid (EACA) and
tranexamic acid (TXA). However, their potency and selectiv-
ity are low, and consequently, these drugs have to be
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administered in high doses, which significantly increases the
risk of adverse effects [1]. Therefore, there is a high demand
for new, more potent and selective, anti-fibrinolytic agents.
Many snake venoms are a rich source of molecules that
interfere with coagulation and fibrinolysis pathways in the
hemostatic system [3]. Both anti- and pro-fibrinolytic activi-
ties have been observed, mostly in the venoms of the
Viperidae snake family [4]. Antiplasmin proteins usually be-
long to the Kunitz/bovine pancreatic trypsin inhibitors (BPTI)
family and so far a number of Kunitz-type protease inhibitors
have been isolated and purified from snake venoms, including
Kunitz inhibitor-I (DrKIn-I) and -II (DrKIn-II) from Daboia
russelii [5], and the textilinins from Pseudonaja textilis [6].
The fibrin(ogen)olytic effect of snake venom toxins results
from different mechanisms, e.g., stimulation of plasminogen
activators from endothelial cells [7], direct plasminogen acti-
vation [8, 9], or direct cleavage and degradation of fibrinogen
and fibrin [10–13]. Most of the molecules which exhibit
fibrin(ogen)olytic activities belong to the snake venom serine
protease (SVSP) and snake venommetalloproteinase (SVMP)
toxin families [4, 14]. Both SVSPs and SVMPs are proteolytic
enzymes of which the latter require zinc ions as metal co-
factors for catalytic activity, and in some cases calcium for
structural stability [14–16].
SVMPs have been recognized as one of the main compo-
nents of venoms responsible for causing pathologies associat-
ed with snakebites [15]. Snakebites remain an important and
neglected public health issue [17] especially in poorer, tropical
areas of the world where access to healthcare is problematic.
Such bites result in extensive mortality (~ 94,000 deaths/
annum) and morbidity (~ 3–5 times the number of annual
deaths), as the result of the hemorrhagic, coagulopathic, neu-
rotoxic, and/or cytolytic effect of different snake venoms [18,
19]. Apart from their high hemorrhagic activities, which is
most profound in the P-III class, SVMPs are reported to ex-
hibit fibrin(ogen)olytic, apoptotic, inflammatory, and factor
Xa and prothrombin-activating activities [14]. Considering
the significant hazard that SVMPs represent to victims of en-
venomation, information on their presence, molecular struc-
ture and bioactive properties will help in the development of
more specific, and thus more effective treatments for snake
envenoming, such as aptamers [20], snake venom toxin inhib-
itors [21, 22], recombinant anti-venoms [23] or chelating
agents [22, 24].
Due to the complex nature of snake venoms, multiple an-
alytical techniques are required for the identification and bio-
chemical characterization of individual toxins. A straightfor-
ward and effective methodology for screening venoms for
selected bioactivities is nanofractionation analytics [25–27].
In this approach, a venom is first separated by liquid chroma-
tography (LC) after which the column effluent is split, with
one part being fractionated with high resolution into a high-
density microtiter well plate (typically 96 to 1536 wells) and
the other part being interrogated simultaneously bymass spec-
trometry (MS) analysis. The collected fractions on the micro-
titer plate are subsequently exposed to a bioassay. As chro-
matographic resolution is essentially maintained, the results of
the bioassay readout can be constructed into a bioactivity
chromatogram, which can be accurately correlated with the
parallel obtainedMS chromatogram. Besides venom research,
the nanofractionation technique also has shown to be useful
for drug-drug interaction profiling [23], environmental analy-
sis [28], and profiling natural extracts [29].
In this study, we present nanofractionation analytics for the
screening of plasmin inhibitors and proteases. We applied the
developed methodology to the analysis of venoms from the
medically relevant viperid snakes Daboia russelii and
Crotalus basiliscus for the presence of plasmin inhibitors as
well as (metallo)proteinases that exhibit fibrin(ogen)olytic ac-
tivity similar to plasmin. Daboia russelii, also known as
Russell’s viper, is responsible for substantial proportion of
snakebite-induced morbidity and mortality in Asia, and causes
diverse symptoms such as coagulopathy, swelling, neurotox-
icity and pain [30].Crotalus basiliscus, known as theMexican
west-coast rattlesnake, as indicated by its name can be found
mainly in Mexico. Envenomation by this snake leads to local
tissue damage, systemic bleeding and hypotension [31].
The fibrin(ogen)olytic proteins were further evaluated for their
activity dependency on metal ions by applying to the
nanofractionated venoms the plasmin bioassay mixture
enriched with zinc and calcium ions, and also in the presence
of the metal chelating agents 1,10-phenanthroline or EDTA.
Plasmin inhibitors and proteolytic enzymes detected by
the applied screening methodology were subsequently
characterized.
Material and methods
Chemicals and biological samples
Human plasmin was purchased from Haematologic
Technologies, Inc. (Essex Junction, VT, USA) and used at
670 μg/mL in 1:1 glycerol/water solutions (v/v). Fluorogenic
substrate H-D-Val-Leu-Lys-AMC was purchased from
BACHEM (Bubendorf, Switzerland) and dissolved in
DMSO to a stock concentration of 40 mM. Leupeptin hydro-
chloride (dissolved in Milli-Q water to obtain a stock of
10 mM), 1,10-phenanthroline, bovine serum albumin (BSA),
calcium chloride, DMSO, EDTA, iodoacetamide, trypsin
from bovine pancreas, and Trizma were all obtained from
Sigma (Zwijndrecht, The Netherlands). Hydrochloric acid
(HCl) was received from Riedel-de-Haën (Zwijndrecht,
The Netherlands), formic acid (FA) and β-mercaptoethanol
were purchased from Merck (Darmstadt, Germany), and
ULC-MS grade acetonitrile (ACN) was obtained from
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Biosolve (Valkenswaard, The Netherlands). Lyophilized
snake venoms were from Daboia russelii (Dr) and Crotalus
basiliscus (Cb), which both are from the Viperidae family. The
Daboia russelii venom (Sri Lankan origin) was provided by
Dr. Nicholas Casewell from the Alistair Reid VenomResearch
Unit, Liverpool School of Tropical Medicine, and the
Crotalus basiliscus venom (Captive bred), was provided by
Dr. Freek Vonk, Naturalis Biodiversity Center. Depending on
the experiment performed, solutions of the venoms were pre-
pared inMilli-Q water at concentrations of 4 mg/ml, 5 mg/mL
or 0.5 mg/ml and stored at − 80 °C.
LC, nanofractionation and MS detection
Bioassay optimization and analyses of crude snake venoms
were performed using a Shimadzu high-performance liquid
chromatography (HPLC) system (‘s Hertogenbosch,
The Netherlands) consisting of a Shimadzu SIL-30 AC
autosampler and a Shimadzu LC-20AB binary pump, which
were interfaced to an Ultima Q-TOF MS instrument (Waters,
Bradfrod, UK).Dr and Cb venoms at a concentration 4 mg/ml
(injected volume, 45 μL) and leupeptin standards (injected
volume, 20 μL) at five different concentrations (ranging from
6 to 200 μM) were separated with a Waters XBridge C18
column (4.6 × 100 mm, particle size 5 μm) (Milford, MA).
The analytical column was protected by a guard column com-
prising the same packing material. Both columns were kept in
a CTD-30 column oven (Shimadzu) set to 37 °C. Gradient
elution was performed employing mobile phase A (98% wa-
ter, 2% ACN, 0.1% FA (v/v/v)) and mobile phase B (98%
ACN, 2% water, 0.1% FA (v/v/v)). The gradient used for sep-
aration started at 0% B with a linear increase to 50% B in
20 min followed by an increase to 90% B in 2 min. The
gradient was held at 90% B for 2 min, and then returned in
1 min to the starting conditions (0% B). Column re-
equilibration was 5 min, resulting in a total analysis time of
30 min. The flow rate was 0.5 ml/min. Using a post-column
flow split, 90% of the eluate was directed via a Shimadzu
SPD-20A UV detector (set at 200 nm) to an in-house devel-
oped nanofractionation system, and the other 10% of the elu-
ate was analyzed with an Ultima Q-TOF mass spectrometer
equipped with electrospray ionization in positive ion mode
(ESI+). The following settings of the ionization source were
used: capillary voltage, 3.25 kV; source temperature, 125 °C;
desolvation temperature, 200 °C; gas flow, 250 L/h. The mass
range was set to 50–2000 m/z.
Detailed information on the nanofractionation system
can be found elsewhere [28, 32]. Briefly, the system was
built from a modified 235 Gilson autosampler, in which a
fused silica capillary extension connected to LC tubing
made of polyether ether ketone (PEEK) was mounted to the
robotic arm, which allowed the capillary needle to move in
xy directions. Fractions of 6 s were collected onto a black 384-
well plate (Greiner Bio One, Alphen aan den Rijn,
The Netherlands) in a serpentine way. After nanofractionation,
the plates were evaporated overnight (O/N) using a RVC 2–33
CD plus maxi concentrator (Salm en Kipp, Breukelen,
The Netherlands) with a rotation speed of 1500 rpm, pressure
of 0.10 mbar, and temperature of 30 °C. After solvent evapo-
ration, the dried plates were stored at − 20 °C prior to
bioassaying. A simplified scheme showing of the analytical
method can be found in Electronic Supplementary Material
(ESM) Fig. S1.
Plasmin bioassay
Screening for snake venom components modifying the activ-
ity of plasmin was performed with an optimized bioassay
mixture containing 100 ng/mL plasmin and 5 μM fluorogenic
substrate H-D-Val-Leu-Lys-AMC dissolved in 100 mM
TRIS-HCl buffer (pH 7.5) containing 0.1% BSA (w/v). The
bioassay optimization results can be found in the ESMSection
S1.1. The bioassay mixture was prepared by adding equal
volumes of substrate and the enzyme solutions in 100 mM
Tris-HCl buffer with 0.1% BSA. The buffer solution was at
room temperature (RT), whereas the enzyme and substrate
stock solutions were kept at − 20 °C. Prior to bioassaying,
the enzyme and the substrate were thawed and diluted in buff-
er contained in two Greiner tubes. The solutions were careful-
ly mixed (for 5 s) to prevent air bubble formation. Directly
after preparing 50 μL of the bioassay mixture was pipetted
over a black 384-well plate (Greiner Bio One, Alphen aan den
Rijn, The Netherlands) using a Multidrop 384 reagent dis-
penser (Thermo Scientific, Ermelo, The Netherlands). A
VarioSkan LUX microplate multimode reader (Thermo
Scientific, Ermelo, The Netherlands) was used to measure
fluorescence of each well kinetically at 380 and 460 nm exci-
tation and emission wavelength, respectively. The temperature
inside the plate reader was set at 37 °C. Each measurement
comprised 10 cycles allowing generation of a kinetic curve,
and subsequent determination of its slope, which was plotted
against the time of nanofraction collection, producing a so-
called bioactivity chromatogram. Negative peaks in the bio-
activity trace represent inhibition of plasmin, and positive
peaks indicate the presence of plasmin inducers or, more like-
ly in the case of venoms, proteases exhibiting an enzymatic
activity similar to plasmin.
The Z′ factor, introduced by Zhang et al. [33], was used as
statistical parameter to assess the quality of the bioassay.
For that, the inhibitor leupeptin (200 μM concentration
representing full enzyme inhibition) and a sample containing
mobile phase A were used as a positive and negative control,
respectively. Both solutions were pipetted over a 384-well plate
at volumes of 10 μL per well using the Multidrop 384 reagent
dispenser. Next, the plates were vacuum-centrifuge evaporated
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and exposed to the plasmin bioassay. Measurements were per-
formed in duplicate.
Bioactive compound identification and sample
purification for proteomics
Reversed-phase (RP) LC and hydrophilic interaction liquid
chromatography (HILIC) orthogonal separation strategy,
fraction collection, proteomics
Identification of bioactive compounds from venoms ofDr and
Cb involved nanofractionation onto 384-well plates with par-
allel high-resolution MS analysis using a Maxis HD quadru-
pole time-of-flight MS (Bruker Daltonics, Bremen,
Germany). For nanofractionation and MS, 5 mg/mlDr venom
and 0.5 mg/ml Cb venom (50 μL injected using a SIL-20AC
autoinjector; Shimadzu, Canby, OR, USA) were separated on
an XBridge BEH300 C18 (4.6 × 150 mm; particle size,
3.5 μm) analytical column placed in a column oven (model
CTO-20AC Shimadzu, Canby, OR, USA) kept at 30 °C. A
binary mobile phase consisting of mixtures of solvent A (98%
water, 2% ACN, 0.1% FA (v/v/v)) and solvent B (98% ACN,
2% water, 0.1% FA (v/v/v)) was used for gradient elution: 0–
50% B in 20 min, 50–90% B from 20 to 24 min, isocratic at
90% B from 24 to 29 min, back to 0% B in 0.1 min. Column
equilibration was then performed for another 10min using 0%
B, resulting in a total analysis time of 40 min. The flow rate
was 0.5 ml/min The MS was equipped with an ESI source
(Apollo) used in positive mode. The capillary voltage was
4.5 kV, and nebulization was done with nitrogen gas
(0.4 bar). Ion desolvation was performed using nitrogen as a
drying gas heated to 200 °C and flowing at a rate of 4 l/min.
Mass accuracy was assured by internal calibration using an
ESI-L low concentration tune mix (Agilent, Santa Clara,
California, USA) in every run.
An orthogonal separation of the two crude venoms was
performed using an Atlantis silica HILIC (4.6 × 150 mm; pore
size, 100 Å; particle size, 3 μm) analytical column. The sep-
aration was performed using gradient elution with solvent A
composed of 98% ACN, 2% water, 0.2% FA (v/v/v) and sol-
vent B of 98% water, 2% ACN, 0.2% FA (v/v/v). The gradient
started at 30% B and increased to 50% B in 15 min. The next
10 min, the gradient rose to 95% B and remained at 95% B for
10 min. Within 2 min, the gradient returned to initial condi-
tions. Column equilibration was set for 23 min at 30% B
resulting in a total analysis time of 60 min. The flow rate
was 0.5 ml/min. MS conditions were the same as used for
RPLC analysis.
The nanofractionated venoms were exposed to the plasmin
bioassay by robotic pipetting of the bioassay mixture to every
second well on the plate. As an eluting compound usually is
distributed over multiple wells, the alternating wells (i.e.,
without bioassay mixture) could be used for other analyses
(e.g., proteomics). From the bioactivity chromatograms, wells
with bioactive compounds were identified and the content of
adjacent wells was subsequently subjected to proteomic anal-
ysis. The content was dissolved in 100 μL water and after
30 min, 50 μL samples were transferred to low-protein bind-
ing Eppendorf tubes containing digestion buffer and reduction
agent for tryptic digestion (see “Tryptic digestion of bioactive
proteins” section).
Throughout the study, leupeptin was used as a time cali-
bration point for accurate correlation of the bioactivity andMS
chromatograms. Leupeptin was analyzed using RPLC and
HILIC separation (ESM Figs. S2A and S2B, respectively).
This experiment enabled calculation of the time delay, which
is observed in the MS data acquisition compared to the
nanofractionation process. This delay is due to differences in
LC-tubing length between the two systems, the column used
and the flow rates applied, and has to be measured after each
change made in the system.
Tryptic digestion of bioactive proteins
Bioactive proteins present in the venoms analyzed underwent
tryptic digestions according the following protocol. Briefly,
reduction of disulfide bonds was performed by adding
50 μL of each bioactive fraction (reconstituted in 100 μL
water) from a nanofractionated snake venom to a solution
containing 75 μL of 25 mM ammonium bicarbonate
(pH 8.2) and 7.5 μL of 0.5% β-mercaptoethanol prepared in
water (v/v). The solutions were shortly vortexed and then in-
cubated at 95 °C for 10 min using a dry block heating ther-
mostat (Bio TDB-100; Biosan Ltd., Riga, Lativa). After
cooling down to room temperature, the solutions were centri-
fuged at a speed of 21,500 rpm for 10 s. Next, the reduced
proteins were alkylated for 30 min with 15 μL of 100 mM
iodoacetamide in the dark at room temperature. After the al-
kylation procedure, proteins were digested by adding 3 μL of
a 0.1 μg/μL trypsin solution prepared in 25 mM ammonium
bicarbonate (pH 8.2). The stock solution of the trypsin used
was 1 mg/ml prepared in 1 mM HCl and stored at − 20 °C.
The samples were incubated for 3 h at 37 °C followed by
addition of an extra 3 μL of the same trypsin solution and then
incubated O/N at 37 °C. The digestion was quenched with
5 μL of 5% formic acid in water (v/v) followed by centrifuga-
tion at 21,500 rpm for 10 s. The collected supernatant was
transferred to LC-MS vials and analyzed with nanoLC-ESI-
MS/MS (see “NanoLC-MS/MS analysis of the tryptic di-
gests” section).
NanoLC-MS/MS analysis of the tryptic digests
Following tryptic digestion, samples were separated and ana-
lyzed with an Ultimate 3000 Nano HPLC system (Thermo
Scientific) interfaced to a Bruker Maxis quadrupole time-of-
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flight MS instrument. Detailed information on these analyses
can be found in the ESM Section S1.2. Identification of pro-
teins was performed with the search engine Mascot (version
2.301). Raw MS data were converted into centroided peak
lists using DataAnalysis version 5.0 (Bruker). The parameters
used for Mascot searches were set as follows: enzyme speci-
ficity, semiTrypsin; missed cleavages, 2; fixed modification,
carbamidomethyl (C); variable modification, oxidation (M)
peptide mass tolerance, 0.1%; fragment mass tolerance,
0.05 Da; no restriction for species was used. The instrument
was set to ESI-QUAD-TOF.
Results and discussion
Evaluation of the plasmin bioassay
Screening snake venoms for plasmin inhibitors and
(metallo)proteinases exhibiting activity similar to plasmin was
performed with a fluorescence based bioassay based on the
protocol reported by Tervo et al. [34]. Bioassay optimization
is described in the ESM section S1.1 and Fig. S3. The opti-
mized bioassay mixture comprised 100 ng/mL end concentra-
tion of plasmin enzyme and fluorogenic aminocoumarin-based
substrate H-D-Val-Leu-Lys-AMC at a final concentration of
5 μM, in 100 mM Tris-HCl buffer (pH 7.5) containing 0.1%
BSA. BSAwas used following the findings by Tervo et al. [34],
who observed that it prolonged the enzymatic activity of plas-
min. In our study, 0.1% BSA increased the signal-to-noise ratio
(S/N) approximately three times and improved the baseline
stability (data not shown).
Awell-performing bioassay should have a statistical Z′ fac-
tor between 0.5 and 1 [33]. To determine the Z′ factor for the
plasmin bioassay, the plasmin inhibitor leupeptin at 200 μM
(causing full inhibition of the enzyme) and a sample contain-
ing mobile phase A were used as positive and negative con-
trols, respectively (Fig. 1). The Z′ value for the plasmin bio-
assay was found to be 0.74, which is considered excellent. The
obtained S/N at maximum inhibition of plasmin was high with
an average S/N of 54.
Optimization and validation of the nanofractionation
approach
To evaluate the performance of the total nanofractionation/
bioassay system, the plasmin inhibitor leupeptin was analyzed
in different concentrations. The experimentally determined
IC50 for leupeptin was 8.4 μM (data not shown). Figure 2
shows bioactivity chromatograms of the different leupeptin
solutions analyzed, which correlated nicely with the parallel
recorded MS data, as shown for the analysis of 100 μM
leupeptin, detected at m/z 427.3. The bioactivity chromato-
grams show inhibition of plasmin as negative peaks.
Leupeptin shows multiple peaks in the XIC at 13.3 and
14.3 min as it comprises a mixture of diasteroisomers of
leupeptin that are generated in solution due to racemization
reactions [35]. The two peaks at 13.3 and 14.3 min are seen in
the bioactivity chromatograms. The peak shapes of the two
diastereoisomeric peaks in the bioactivity trace could exactly
be correlated by the parallel obtained MS chromatogram. The
sigmoidal concentration–response relation of the bioassay
causes the bioactivity peaks to show broadening at high con-
centrations leupeptin injected, which is quite common for this
type of analyses [26, 36]. Chromatographic band dispersion,
spreading of eluting compounds over multiple wells and ad-
ditional dilution of the dried wells after reconstitution of the
deposited components in the wells with bioassay mixture,
results in a difference between bioassay concentration and
injected concentration, denoted as dilution factor [37], which
was ~ 3.2.
Profiling plasmin inhibition and proteolytic activity
in Cb and Dr venoms
Venoms of Cb and Dr were analyzed for (1) the presence of
proteins exhibiting inhibitory activity towards plasmin, and
(2) the presence of proteases exhibiting plasmin-like activities
and/or plasmin activators. Figure 3 shows results obtained
after injection of 4 mg/ml of the venoms. In the bioactivity
chromatograms of Cb venom (Fig. 3a), no negative peaks
were observed implying that Cb venom did not contain com-
ponents with significant antiplasmin (anti-fibrinolytic) activi-
ty. To our knowledge, no anti-fibrinolytic activities of Cb ven-
om have been reported in the literature. However, the bioac-
tivity chromatograms of Cb venom showed a clear positive
peak between 17 and 18 min, indicating protein components
with possible proteolytic and fibrin(ogen)olytic activity. Cb
venom is known to have fibrinolytic properties and a number
of fibrinolytic enzymes have previously been isolated from
this venom [31, 38, 39]. To investigate whether the positive
peak observed resulted from proteases exhibiting proteolytic
properties similar to plasmin, or resulted from a plasmin ac-
tivity inducer, variants of the bioassay were applied (see
below).
The analysis of the venom of Dr resulted in bioactivity
chromatograms showing clear inhibition of plasmin
(Fig. 3a). Injection of a venom sample of 4 mg/ml showed
multiple negative peaks eluting at 8.9 and 9.9 min, clearly
indicating the presence of antiplasmin/anti-fibrinolytic activi-
ty. Dr venom has previously been reported to contain the
Kunitz-type protease inhibitors DrKIn-I and -II which exert
anti-fibrinolytic activity. Some reports, however, showed that
Dr venoms also contain SVSPs and SVMPs, which could
potentially exert fibrin(ogen)olytic properties [40, 41].
However, in our study, positive peaks were not observed.
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For further investigation of the increased enzyme activities
observed for the two venoms, six different variants of the
plasmin bioassay were applied. In the first variant, the bioas-
say mixture was prepared without the addition of plasmin to
test whether the active protein is a plasmin analogue that con-
verts similar substrates or is a plasmin activator. In the second
and third variants, the bioassay mixture was prepared without
plasmin and was enriched with calcium (1 mM) or zinc
(0.2 mM) ions, respectively, to determine whether bioactivity
could be ascribed to a metalloproteinase and, if so, to differ-
entiate between calcium or zinc dependency. To confirm that
the resulting bioactive protein is a metalloproteinase, in the
fourth and fifth variant of the bioassay, the metal ion chelators
EDTA (50 mM) or 1,10-phenanthroline (5 mM) were added,
while again excluding plasmin from the mixture. The chelator
1,10-phenanthroline specifically binds zinc ions, deactivating
zinc-dependent metalloproteinases only, whereas EDTA che-
lates both zinc and calcium ions [42]. In the sixth and final
variant, 1,10-phenanthroline was added to the full bioassay
mixture, in order to deactivate SVMPs (if present) and allow
the detection of inhibitors that are co-eluting with SVMPs.
Results from the analyses of both venoms using the six
assay variants are shown in Fig. 3a–f for Cb and Dr, respec-
tively. An extensive discussion of the results of these experi-
ments can also be found in the ESM Section S2.1. Briefly, in
the venom of Cb, the major positive peak was also observed
when plasmin was not included in the bioassay mixture. This
indicates that the bioactive protein detected is not a plasmin
inducer, but an enzyme that is capable of converting the sub-
strate. Subsequent experiments (bioassay variants 2–5)
showed that the activity of the bioactive protein increased
about threefold (compared to the results obtained with sub-
strate only [variant 1]) when calcium ions were added to the
bioassay mixture, indicating possible calcium dependency or
increased stability of the protein. The addition of zinc ions did
not affect the intensity of the bioactivity peak. To assure that
the changes observed in the bioassay are not a result of the
variation between different plates/bioassays tested, additional
experiments confirming the dependence of the bioactive com-
pounds on metal ions were performed. Two bioassay mix-
tures, with added calcium and zinc ions, respectively, were
pipetted into alternating wells of one microtiter well
plate containing nanofractionated venom. This was done to
exclude potential inter-experiment variations between
nanofractionated runs. The results (ESM Fig. S4a) showed
an activity-inducing effect of the calcium ions on the eluted
bioactive proteins, confirming the results of the earlier exper-
iments. Figure 3 shows that, in the case of Dr venom, no
increased enzyme activity was observed, indicating that the
bioactive compounds detected (Fig. 3a–f) were predominantly
plasmin inhibitors (anti-fibrinolytic agents) [43].
Identification of the bioactives
For identification of the observed bioactive proteins, the
two crude venoms were each nanofractionated twice using
the orthogonal chromatographic separation mechanisms
RPLC and HILIC. The resulting nanofractionated plates
were then exposed to the bioassay mixture by pipetting it
to the even rows, leaving the odd rows empty (containing
only the dried fractions). Based on the bioactivity chro-
matograms resulting from these experiments, information
on the elution time of the bioactives, their positions in the
well plates and their molecular weight was obtained for
each stationary phase used. Subsequently, wells containing
dried fractions which were not exposed to the bioassay
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Fig. 1 Assessment of the
bioassay performance. The Z′-
factor for the bioassay was
calculated to be 0.74. Positive
control (C+) wells contain mobile
phase A (n = 96); negative control
(C−) wells contain 200 μM
leupeptin (n = 96). Thewells were
evaporated to dryness prior to the
bioassay
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mixture, but which were adjacent to wells with bioactive
proteins, were subjected to tryptic digestion and proteomic
analysis. The bioactivity chromatograms correlated to cor-
responding MS data for Cb and Dr venoms are presented
in Fig. 4. The bioactivity chromatogram for Cb venom
(0.5 mg/ml injected concentration) analyzed with RPLC
(Fig. 4) displayed a clear positive peak at 19.5 min. The
HILIC analysis of Cb venom showed a bioactive compo-
nent peak eluting as a sharp peak between 5.7 and 6.5 min.
The m/z values that correlated with the bioactivity peak for
both bioactivity chromatograms were 1264.92 (charge
state + 11 protein mass 13,903.06), and 759.70 (charge
state + 3; peptide mass 2276.05). Based on the earlier ex-
periments in which different variants of the plasmin assay
were used, the bioactive is expected to be a calcium-
dependent protease. However, no protein with a molecular
mass between 20 and 100 kDa (i.e., the mass range of
known snake venom metalloproteinases) was observed,
most likely due to the limited ionization efficiency
achieved for larger intact proteins. The highest mass that
was detected with RPLC-MS and HILIC-MS was ~
15 kDa, which matches well with the phospholipase A2
(PLA2) family (13–15 kDa). Considering that venom is a
complex mixture, some peptides and proteins will not be
separated and will coelute making the determination of the
bioactive peptides more difficult. The presence of the mass
(15 kDa) can be explained by coelution of PLA2 with the
real bioactive observed in both bioactivity chromatograms
[3, 44]. Slightly different results were obtained from the
proteomic analysis of the bioactive wells. Mascot search
results obtained from the nanoLC-MS data for the trypsin-
digested bioactive proteins revealed the presence of
Time (min)
a
b
c
d
e
f
In
te
n
s
it
y
R
F
U
/m
in
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
0
5000
10000
15000
XIC m/z 427.3025 Da [M+H]+
Fig. 2 Evaluation of the overall
performance of the
nanofractionation system using
the plasmin inhibitor leupeptin,
which was nanofractionated at
five concentrations injected. (a)
6.3 μM. (b) 25 μM. (c) 50 μM.
(d) 100 μM. (e) 200 μM. (f) The
extracted ion chromatogram (m/z
427.3, [M +H]+) of the analysis
of 100 μM leupeptin with online
LC-MS. RFU, relative
fluorescence units
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peptide sequences that matched SVSPs and SVMPs.
Together, five proteins were found in the samples obtained
from RP analysis, and eight proteins were found after
HILIC. The peptide sequences found in the venom sample
analyzed with RPLC matched the proteins catroxase-1
(protein coverage, 10%; protein score, 99), for which two
distinct peptides were found, and catroxase-2 (protein cov-
erage 17%; protein score, 91), with two distinct peptides.
Both of the catroxases came from Crotalus atrox. A match
was also found with a serine protease from Crotalus
durissus (protein coverage, 13%; protein score, 233), for
which two peptides were found. Although the Mascot re-
port showed the two catroxases to fit into the family of
SVSPs, the protein catroxase on several occasions has
been reported to be a SVMP [13, 45]. For example,
Chiou et al. [13] reported catroxase as a fibrinolytic pro-
tein that belongs to the family of SVMPs, as it was found
to be inhibited by EDTA. This discrepancy can be ex-
plained by the fact that several catroxases exist and they
are a mixture of SVSPs and SVMPs (http://www.uniprot.
org/uniprot/?query=CATROXASE&sort=score). It is
important to mention, however, that the sequence of
SVMP catroxase has been only partially determined. It is
possible that our sample contains a bioactive protein with
a sequence that matched partially with SVSP cartoxases
found in C. atrox; however, it still possesses metal-
dependency, as showed by its inhibition with EDTA.
This information supports our earlier results suggesting
that the bioactive could be a fibrinolytic calcium-
dependent metalloproteinase. In addition, we recovered
peptide sequences matching SVSPs from Protobothrops
jerdonii (protein coverage 8%, protein score 100) with a
single matched peptide, and an acidic phospholipase A2
from Crotalus viridis (protein coverage 18%, protein score
59) with two peptides matched. The SVMP atrolysin-d,
which is known to have calcium and zinc binding sites
(http://www.uniprot.org/uniprot/P15167), was found after
HILIC-MS analysis (protein coverage 3%, protein score
123), for which a single peptide was found. Detailed in-
formation obtained from the Mascot searches revealing the
Fig. 3 (a–f) Bioactivity
chromatograms obtained for Cb
and Dr venoms using the
following assay variants. (a) Full
plasmin bioassay mixture
containing plasmin and substrate.
(b) Bioassay mixture containing
only the substrate. (c) Bioassay
mixture containing only the
substrate and buffer enriched with
zinc ions. (d) Bioassay mixture
containing only the substrate and
buffer enriched with calcium ions.
(e) Bioassay mixture containing
only the substrate and buffer
enriched with EDTA. (f) Bioassay
mixture containing plasmin,
substrate and 1,10-
phenanthroline. (g) Total-ion
chromatogram obtained for Cb
and Dr venoms with online
parallel LC-MS. The rectangular
gray shades indicate the elution of
the bioactive peaks. Photos of the
snakes: Crotalus basiliscus
(source: Shutterstock/Bernhard
Richter); Daboia russelii (source:
Shutterstock/Meet Poddar). RFU,
relative fluorescence unit
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protein coverage and scores for Cb venom analyzed with
RPLC and HILIC can be found in ESM Table S2.
When Dr venom (injected concentration, 5 mg/ml) was
analyzed by RPLC-MS and HILIC-MS, the observed bioac-
tivity peaks correlated with m/z 931.04 Da (charge state + 8;
peptide mass 7440.25) and m/z 984.88 (charge state + 7; pep-
tide mass 6887.10) (Fig. 4). Further analysis of the trypsin-
digested bioactive well with nanoLC-MS andMascot analysis
obtained after RPLC revealed the presence of four proteins,
and in the case of HILIC analysis, the number of found pro-
teins was five. The matched proteins include the Kunitz-type
serine protease inhibitor C6 from Daboia siamensis venom
(protein coverage, 43%; protein score, 343) for which five
peptides were found, and Kunitz-type serine protease inhibi-
tors 3 and 4, both from Daboia russelii venom (protein cov-
erage, 36%; protein score, 58, three matched peptides; and
protein coverage, 33%; protein score, 125, one matched pep-
tide, respectively). For the proteomic analysis of bioactive
fractions collected after HILIC separation, the best match
was for the co-eluting basic PLA2 VRV-PL-VIIIa (protein
coverage, 87%; protein score, 2173), for which 17 peptides
were found, and PLA2 VRV-PL-V (protein coverage, 71%;
protein score, 1935), for which seven peptides were found.
Both proteins were found to be from Daboia russelii venom.
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Fig. 4 Correlation of bioactivity
and MS chromatograms obtained
for Cb (C. basiliscus) and Dr (D.
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Kunitz-type serine protease inhibitor 3 was also found in the
HILIC bioactive fraction, however, at a protein score of 65
and protein coverage of 20%, with a single peptide matched.
Detailed results from Mascot analysis listing all protein and
peptides found together with the protein and peptides scores,
% coverage, observed and expected masses of the peptides
can be found in ESM Table S3.
Conclusions
In this study, a nanofractionation platform was developed and
applied for the screening of snake venoms for plasmin inhib-
itors and (metallo)proteinases with similar activity to plasmin.
A 384-well format plate reader fluorescence assay for plasmin
activity was optimized and implemented in the platform. The
usefulness of the methodology was demonstrated by analyz-
ing venoms of the snakes Daboia russelii and Crotalus
basiliscus. In Dr venom, plasmin inhibitors were detected
and identified by downstream proteomic analysis. In Cb
venom, fibrin(ogen)olytic enzymes that act in a manner
similar to plasmin were found. These enzymes were shown
to be potentially calcium dependent proteases that exhibited
similarity to known SVMP venom toxins. The method
developed is a reliable and high-throughput screening tool that
helps in discovering new drug leads by exposing individual
proteins present in snake venoms to a bioassay mixture con-
taining a drug target of interest. The parallel MS analysis and
off-line proteomic studies that follow the bioactivity assess-
ment allow for bioactive protein identification in a high-
throughput manner. Understanding the composition of snake
venoms, in particular toxins that are responsible for the life
debilitating and life-threatening manifestation of snakebites,
may also aid in the development of new toxin-specific anti-
venoms that have already been demonstrated to have the po-
tential to neutralize toxins in venoms of snakes species that are
geographically and phylogenetically distinct [22].
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